In a report released yesterday, Justin Zelin from BTIG maintained a Hold rating on Carisma Therapeutics (CARM – Research Report). The company’s ...

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has earned an average recommendation of “Hold” from the seven ...

Fintel reports that on December 10, 2024, BTIG downgraded their outlook for Carisma Therapeutics (NasdaqGM:CARM) from Buy to Neutral. Analyst Price Forecast Suggests 1,361.19% Upside As of ...

Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna. Vaishali Prayag ...

Fintel reports that on December 11, 2024, Evercore ISI Group downgraded their outlook for Carisma Therapeutics (NasdaqGM:CARM) from Outperform to In-Line. Analyst Price Forecast Suggests 1,697.20% ...

This page features the latest news about the Carisma Therapeutics stock. CARM stock touches 52-week low at $0.38 amid market challenges In a challenging market environment, shares of Eleven ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.